Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Combined use of a prototype oncolytic poxvirus with guided radiation therapy for targeted tumour treatment
EF 2013-14
Résumé
Oncolytic virus therapy using poxviruses to preferentially infect and kill cancer cells is not a new concept, and has been investigated for the past decade. Previous research and clinical studies have shown promise in using thymidine kinase (TK) deficient poxviruses to kill tumour cells due to their reduced virulence in animals, and preferential replication in actively dividing cells. However, due to the large size of a tumour mass, it is unlikely that oncolytic virus therapy alone would be sufficient enough to rid the body of cancerous cells. Rather, viral therapy is best used to promote an immune response to the tumour and for ridding the adjacent tissues of low levels of metastatic cells. Thus, it has been suggested that oncolytic virus treatment be used in conjugation with another form of treatment to remove the bulk of the tumour mass.
Image-guided radiation therapy (IG-RT) combines cancer imaging with computer-controlled modulation of dose delivery to precisely direct radiation to the tumour site, and minimize impact on surrounding tissue. However, concerns have been raised that, although damage to normal surrounding tissue is minimized, cancerous cells on the peripheral of the tumour might be missed as well, therefore allowing for an increased risk of tumour re-occurrence. The effects of using oncolytic viruses combined with radiation therapy for tumour treatment is a concept which has not yet been explored.
We hypothesize that combining oncolytic virus treatments with IG-RT will create synergistic effects that will be more effective at controlling tumour growth than either treatment would be on its own. The bulk of the tumour mass will be killed by the radiation therapy, while the oncolytic viruses will seek out and destroy any residual cancer cells and thus prevent tumour recurrence.
We would like to first determine the effects on viral growth kinetics and cell survival when vaccinia viruses (poxvirus) are cultured on cells pre-treated with ionizing radiation . To accomplish this, mutants of vaccinia virus (VAC) will be prepared which will allow for preferential growth in tumour tissue, making it less aggressive and more tumour selective. This will be accomplished by deletion of the viral F4L and J2R genes of VAC. Human breast cancer cells available from the collaborating Evan’s and Hitt labs will then be irradiated, followed by inoculation with our oncolytic VAC. Kinetics of virus growth, virus yield, and cell killing will then be analyzed to determine how each is effected by the radiation treatment. The order of treatment and the times between treatments will also be explored to optimize the effectiveness of delivery.
Once we have determined the effects of irradiation on virus growth and cell killing, and optimized treatment conditions, we will then compare the therapeutic effectiveness of combining IG-RT and viral oncolytic therapy, with either therapy used alone, in a mouse breast cancer tumour model. After treatment, tumour and virus growth in the animal will be monitored using fluorescence imaging with an IVIS imager, and survival curves will be analyzed. A collaborator within the institute, Dr. David Murray, will provide assistance with the IG-RT and will be responsible in managing the control of radiation delivery and dosing. The Evans and Hitt labs will provide expertise in virology and in devising the animal tumour models.
The therapeutic effectiveness of combining IG-RT with oncolytic viruses has not yet been studied in any detailed way and yet there is good reason to believe such effects might be obtainable. If we can demonstrate synergistic killing of cancer cells and tumours, using state-of-the-art technologies, it would revolutionize cancer treatment in Canada.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
312023
Name
Umer Brittany
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Combined use of a prototype oncolytic poxvirus with guided radiation therapy for targeted tumour treatment
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Combination Therapy; Guided Radiation; Oncolytics; Viral Therapy
Abstract
Oncolytic virus therapy using poxviruses to preferentially infect and kill cancer cells is not a new concept, and has been investigated for the past decade. Previous research and clinical studies have shown promise in using thymidine kinase (TK) deficient poxviruses to kill tumour cells due to their reduced virulence in animals, and preferential replication in actively dividing cells. However, due to the large size of a tumour mass, it is unlikely that oncolytic virus therapy alone would be sufficient enough to rid the body of cancerous cells. Rather, viral therapy is best used to promote an immune response to the tumour and for ridding the adjacent tissues of low levels of metastatic cells. Thus, it has been suggested that oncolytic virus treatment be used in conjugation with another form of treatment to remove the bulk of the tumour mass.
Image-guided radiation therapy (IG-RT) combines cancer imaging with computer-controlled modulation of dose delivery to precisely direct radiation to the tumour site, and minimize impact on surrounding tissue. However, concerns have been raised that, although damage to normal surrounding tissue is minimized, cancerous cells on the peripheral of the tumour might be missed as well, therefore allowing for an increased risk of tumour re-occurrence. The effects of using oncolytic viruses combined with radiation therapy for tumour treatment is a concept which has not yet been explored.
We hypothesize that combining oncolytic virus treatments with IG-RT will create synergistic effects that will be more effective at controlling tumour growth than either treatment would be on its own. The bulk of the tumour mass will be killed by the radiation therapy, while the oncolytic viruses will seek out and destroy any residual cancer cells and thus prevent tumour recurrence.
We would like to first determine the effects on viral growth kinetics and cell survival when vaccinia viruses (poxvirus) are cultured on cells pre-treated with ionizing radiation . To accomplish this, mutants of vaccinia virus (VAC) will be prepared which will allow for preferential growth in tumour tissue, making it less aggressive and more tumour selective. This will be accomplished by deletion of the viral F4L and J2R genes of VAC. Human breast cancer cells available from the collaborating Evan’s and Hitt labs will then be irradiated, followed by inoculation with our oncolytic VAC. Kinetics of virus growth, virus yield, and cell killing will then be analyzed to determine how each is effected by the radiation treatment. The order of treatment and the times between treatments will also be explored to optimize the effectiveness of delivery.
Once we have determined the effects of irradiation on virus growth and cell killing, and optimized treatment conditions, we will then compare the therapeutic effectiveness of combining IG-RT and viral oncolytic therapy, with either therapy used alone, in a mouse breast cancer tumour model. After treatment, tumour and virus growth in the animal will be monitored using fluorescence imaging with an IVIS imager, and survival curves will be analyzed. A collaborator within the institute, Dr. David Murray, will provide assistance with the IG-RT and will be responsible in managing the control of radiation delivery and dosing. The Evans and Hitt labs will provide expertise in virology and in devising the animal tumour models.
The therapeutic effectiveness of combining IG-RT with oncolytic viruses has not yet been studied in any detailed way and yet there is good reason to believe such effects might be obtainable. If we can demonstrate synergistic killing of cancer cells and tumours, using state-of-the-art technologies, it would revolutionize cancer treatment in Canada.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Umer, Brittany
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~